Printer Friendly

U.S. BIOSCIENCE APPOINTS REYNOLDS SENIOR MEDICAL DIRECTOR FOR R&D; CONLON AND KOUSSAI JOIN BIOSTATISTICS DEPARTMENT

 WEST CONSHOHOCKEN, Pa., March 9 /PRNewswire/ -- U.S. Bioscience, Inc. (AMEX: UBS) announced today the appointment of Ralph D. Reynolds, M.D. as senior medical director for research and development of this pharmaceutical firm. He reports to Robert L. Capizzi, M.D., executive vice president, worldwide research and development. Dr. Reynolds' responsibilities include the multi-center clinical trials required for regulatory approval of compounds in the company's research pipeline.
 Prior to joining U.S. Bioscience, Dr. Reynolds was associate director of oncology at Adria Laboratories. His 30 years of experience in cancer treatment includes posts as professor, consultant and clinical investigator, and he has authored over 100 manuscripts relating to cancer treatment and internal medicine. Dr. Reynolds is board certified in internal medicine and medical oncology and is a fellow of the American College of Physicians and of the Royal College of Physicians of Great Britain. He retired with the rank of colonel in 1982 after 24 years in the United States Air Force Medical Service.
 The company also announced the appointment of John C. Conlon, Ph.D. as director of biostatistics and Alex D. Kouassi, Ph.D. as biostatistician. Dr. Conlon was previously director of biostatistics at Allergan, Inc. and has 11 years of experience in his field within the pharmaceutical industry. Dr. Conlon has been responsible for the preparation of a number of New Drug Applications in a broad range of therapeutic areas. Dr. Kouassi joined the company from Boehringer Mannheim Pharmaceuticals and earlier had been with Merck Sharp & Dohme. Their responsibilities include the design and analysis of clinical studies of the company's compounds.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of compounds, including two products for which new drug applications have been filed and two others in the late stages of development. One compound, altretamine, is marketed under the name Hexalen(R) in the United States for the treatment of ovarian cancer.
 -0- 3/9/93
 /CONTACT: Robert I. Kriebel, senior vice president - finance and administration of U.S. Bioscience, 215-832-4503/
 (UBS)


CO: U.S. Bioscience, Inc. ST: Pennsylvania IN: MTC SU: PER

AH-SB -- NY063 -- 4580 03/09/93 14:24 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1993
Words:388
Previous Article:GRUPO GIGANTE REPORTS 1992 RESULTS
Next Article:EQUITABLE RESOURCES ANNOUNCES OFFSHORE DISCOVERY
Topics:


Related Articles
Senior Pharmaceutical Industry Executives Join Pharsight Management Team.
Fifty-Five Honorees Named Fellows by the American Statistical Association.
Genentech Names Corsee Sanders Vice President, Biometrics and Business Operations, Medical Affairs.
TM Bioscience Appoints Paul Lucas To Chairman Of The board.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters